BofA analyst Travis Steed lowered the firm's price target on DexCom to $80 from $100 and keeps a Buy rating on the shares following the company's analyst day and manufacturing tour. The firm updated its target for lower peer multiples and now uses 25-times its 2027 EPS estimate, versus 35-times previously, the analyst noted.
